Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
255 participants
INTERVENTIONAL
2006-01-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
NCT01701362
A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
NCT00407745
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
NCT00629681
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00143156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
pregabalin
pregabalin
Placebo
Placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pregabalin
pregabalin
Placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* NeP not due to trauma, and not peripheral pain
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Genk, , Belgium
Pfizer Investigational Site
Liège, , Belgium
Pfizer Investigational Site
Liège, , Belgium
Pfizer Investigational Site
Pellenberg, , Belgium
Pfizer Investigational Site
Wilrijk, , Belgium
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Aarhus C, , Denmark
Pfizer Investigational Site
Hvidovre, , Denmark
Pfizer Investigational Site
HUS, , Finland
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Montescano (PV), , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Tilburg, North Brabant, Netherlands
Pfizer Investigational Site
Amsterdam, North Holland, Netherlands
Pfizer Investigational Site
Alkmaar, , Netherlands
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Kampen, , Netherlands
Pfizer Investigational Site
Roosendaal, , Netherlands
Pfizer Investigational Site
Almada, , Portugal
Pfizer Investigational Site
Amadora, , Portugal
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Funchal, , Portugal
Pfizer Investigational Site
Guimarães, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Bucharest, , Romania
Pfizer Investigational Site
Bucharest, , Romania
Pfizer Investigational Site
Bucharest, , Romania
Pfizer Investigational Site
Iași, , Romania
Pfizer Investigational Site
Linköping, , Sweden
Pfizer Investigational Site
Lund, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Bern, , Switzerland
Pfizer Investigational Site
Geneva, , Switzerland
Pfizer Investigational Site
Birmingham, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Leeds, , United Kingdom
Pfizer Investigational Site
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
van Seventer R, Serpell M, Bach FW, Morlion B, Zlateva G, Bushmakin AG, Cappelleri JC, Nimour M. Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain. Health Qual Life Outcomes. 2011 Mar 25;9:17. doi: 10.1186/1477-7525-9-17.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081064
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.